DYRK1A and Dravet syndrome: Therapeutic strategies based on reducing the activity of DYRK1A (e.g. leucettine L41 and a green tea extract enriched in epigallocatechin gallate) have shown beneficial effects in DS models, including Dp(16)1Yey mice [38, 56, 57].